Hengrui medicine reacquires the fever, and PD-1 monoclonal antibody has obtained two new stage III clinical approvals for indications

On July 16, Hengrui pharmaceutical announced that it had recently received the notice of clinical trial of combination therapy of carrizumab for injection (shr-1210) approved and issued by the State Drug Administration Carrizumab (shr-1210) is a humanized anti-PD-1 monoclonal antibody It can bind to human PD-1 receptor and block the PD-1 / PD-L1 pathway, restore the anti-tumor immunity of the body, thus forming the foundation of cancer immunotherapy In May 2019, carrizumab for injection of the company was approved for the market of indications of relapsed and refractory classic Hodgkin's lymphoma It is found that the anti-PD-1 antibody products nivolumab, pembrolizumab and cemiplimab rwlc have been approved for marketing Nivolumab was developed by Bristol Myers Squibb with the trade name of opdivo, which was approved to be listed in the United States as early as 2014; pembrolizumab was developed by Merck sharp & Dohme with the trade name of keytruda, which was approved to be listed in the United States as early as 2014; ceiplimab rwlc was jointly developed by regeneron and Sanofi Aventis with the trade name of libtayo, It was approved for listing in the United States as early as 2018 Two of them, nivolumab and pembrolizumab, have been approved for marketing in China At present, the similar anti-PD-1 monoclonal antibody injection developed by Xinda biology and Junshi biology has been approved for listing in 2018, and the related drugs of Baiji Shenzhou and other enterprises are in the stage of listing application and approval After querying IMS database, the global sales volume of anti-PD-1 antibody in 2018 is about US $14178.02 million, and the domestic sales volume is about US $6.4375 million Up to now, the R & D cost of the product project has been about 548.66 million yuan.